S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Exopharm Stock Price, News & Analysis (ASX:EX1)

A$0.40
0.00 (0.00 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
A$0.40
Now: A$0.40
A$0.40
50-Day Range N/A
52-Week Range
A$0.35
Now: A$0.40
A$0.67
Volume5,025 shs
Average VolumeN/A
Market Capitalization$38.19 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing clinical human therapeutics in Australia. It is developing Plexaris, an exosome derived from human platelets; and Exomeres, an exosome derived from adult stem cells. The company was founded in 2003 and is headquartered in Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9111 0026

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28,789.00
Cash FlowA$0.04 per share
Book ValueA$0.06 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$38.19 million
Next Earnings DateN/A
OptionableNot Optionable

Receive EX1 News and Ratings via Email

Sign-up to receive the latest news and ratings for EX1 and its competitors with MarketBeat's FREE daily newsletter.


Exopharm (ASX:EX1) Frequently Asked Questions

What is Exopharm's stock symbol?

Exopharm trades on the ASX under the ticker symbol "EX1."

Has Exopharm been receiving favorable news coverage?

Press coverage about EX1 stock has trended very negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exopharm earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Exopharm.

Who are some of Exopharm's key competitors?

Who are Exopharm's key executives?

Exopharm's management team includes the folowing people:
  • Dr. Ian Dixon MBA, Ph.D., Company Founder, Technology Co-Founder, MD & Director
  • Dr. Gregor Lichtfuss, COO & Technology Co-Founder
  • Mr. David Rodney Parker B.Com, SAFin, ACIS, Non-Exec. Director & Company Sec. (Age 40)

What is Exopharm's stock price today?

One share of EX1 stock can currently be purchased for approximately A$0.40.

How big of a company is Exopharm?

Exopharm has a market capitalization of $38.19 million and generates $28,789.00 in revenue each year. View Additional Information About Exopharm.

What is Exopharm's official website?

The official website for Exopharm is http://www.exopharm.com/.

How can I contact Exopharm?

The company can be reached via phone at 61 3 9111 0026.


MarketBeat Community Rating for Exopharm (ASX EX1)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  3
MarketBeat's community ratings are surveys of what our community members think about Exopharm and other stocks. Vote "Outperform" if you believe EX1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EX1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel